Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori

Caselli, Michele; Trevisani, Lucio; Tursi, Antonio; Sartori, Sergio; Ruina, Marco; Luzzi, Ida; Gaudenzi, Piergiorgio; Alvisi, Vittorio; Gasbarrini, Giovanni

doi:10.1097/00042737-199701000-00012

Cited by 42 publications

(30 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Azithromycin is active against H pylori when it is combined with metronidazole and omeprazole. 22 It is also effective, in combination with metronidazole, against common dental and bronchial pathogens. 23 Macrolides have additionally been shown to have antiinflammatory activity, 24,25 which represents another possible mechanism responsible for their beneficial effects in the present study.…”

Section: Discussionmentioning

confidence: 99%

Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes

et al. 2002

View full text Add to dashboard Cite

Background-Infection with Helicobacter pylori and Chlamydia pneumoniae is associated with coronary heart disease.We conducted an intervention study using antibiotics against these bacteria in patients with acute coronary syndromes to determine whether antibiotics reduce inflammatory markers and adverse cardiac events. Methods and Results-Patients (nϭ325) admitted with acute myocardial infarction or unstable angina (acute coronary syndromes) were randomized to receive a 1-week course of 1 of 3 treatment regimens: (1) placebo; (2) amoxicillin (500 mg twice daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily); or (3) azithromycin (500 mg once daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily). Serum fibrinogen, white cell count, and high-sensitivity C-reactive protein were measured at study entry and at 1, 3, and 12 months during follow-up. Cardiac death and readmission with acute coronary syndrome were considered clinical end points. Patients were followed for 1 year. C-reactive protein levels were reduced (Pϭ0.03) in unstable angina patients receiving amoxicillin, and fibrinogen was reduced in both patient groups receiving antibiotics (Pϭ0.06). There were 17 cardiac deaths and 71 readmissions with acute coronary syndrome. No difference in frequency or timing of end points was observed between the 2 antibiotic groups. At 12 weeks, there was a 36% reduction in all end points in patients receiving antibiotics compared with placebo (Pϭ0.02). This reduction persisted during the 1-year follow-up. Neither C pneumoniae nor H pylori antibody status was significantly related to response to treatment. Conclusions-Antibiotic treatment significantly reduced adverse cardiac events in patients with acute coronary syndromes, but the effect was independent of H pylori or C pneumoniae seropositivity.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Clarithromycin in combination with a PPI and a nitroimidazole may be replaced by azithromycin without loss of eYcacy. Whereas Caselli et al 27 achieved a 93% eradication rate using azithromycin 500 mg for three days, Seelis et al 28 achieved only 47% with the same dose, but 93% using azithromycin 500 mg for six days. originally used a once daily standard dose.…”

Section: Dose Of Macrolidementioning

confidence: 98%

The European meeting on Helicobacter pylori: therapeutic news from Lisbon

Peitz¹,

Menegatti²,

Vaira³

et al. 1998

Gut

View full text Add to dashboard Cite

“…Azithromycin is said to be a compound similar to clarithromycin for the eradication of H. pylori 28,29 . Unfortunately this antibiotic is not always applicable, since it has a lower reliability than clarithromycin for a 3-day Per protocol (n = 28) 9 / 32% 13% -50%…”

Section: Discussionmentioning

confidence: 99%

Low efficacy of an ultra-short term, once-daily dose triple therapy with omeprazole, azithromycin, and secnidazole for Helicobacter pylori eradication in peptic ulcer

et al. 2002

View full text Add to dashboard Cite

PURPOSE:To determine the eradication rate of an ultra-short treatment schedule for Helicobacter pylori infection in a population with peptic ulcers, using omeprazole, secnidazole, and azithromycin in a once-daily dose for 3 days.METHODS: Thirty patients with peptic ulcer diagnosed by upper endoscopy and for Helicobacter pylori infection by rapid urease test and histologic examination received omeprazole 40 mg, secnidazole 1000 mg, and azithromycin 500 mg, administered once daily for 3 days. A follow-up exam was performed 12 weeks after the end of the treatment. Patients who were negative for Helicobacter pylori infection by rapid urease test and histologic examination were considered cured.RESULTS: Patients were predominantly female, and the mean age was 50 years. Duodenal peptic ulcer was found in 73% of the patients. Eradication was achieved in 9 of the 28 (32%) patients as determined from the follow-up endoscopic exam. The eradication rate by intention to treat was 30%. Side effects were present in 3% of the patients, and compliance to treatment was total.CONCLUSIONS: In spite of the low rate of side effects and good compliance, the eradication index was low. A possible drawback of this therapy is that it reduces the efficacy of macrolide and nitroimidazole compounds in subsequent treatments. DESCRIPTORS: Peptic Ulcer/Treatment. Helicobacter pylori/Eradication. Secnidazole/Therapeutic use. Azithromycin/ Therapeutic use. Omeprazole/Therapeutic use.

show abstract

Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori

Cited by 42 publications

References 0 publications

Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes

Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes

The European meeting on Helicobacter pylori: therapeutic news from Lisbon

Low efficacy of an ultra-short term, once-daily dose triple therapy with omeprazole, azithromycin, and secnidazole for Helicobacter pylori eradication in peptic ulcer

Contact Info

Product

Resources

About